Skip to content

Corcept Therapeutics CORT Long-term accrued government rebates

Long-term accrued government rebates at other companies

Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS
$70.72M+49.2%
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS
$12.69M+19.7%
Alkermes logo
AlkermesALKS
$189.03M-1.3%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$18.4B-2.0%
Alkermes logo
AlkermesALKS
$38.6M+94.0%
Molina Healthcare logo
Molina HealthcareMOH
$1.69B-9.6%

Other financials

Income statement

See full
Revenue$164.9M+4.9%
Gross profit$162.0M+4.7%
Operating income-$49.6M-1,552%
Net income-$31.8M-255%
EPS (diluted)-$0.30-276%

Balance sheet

See full
Cash & equivalents$110.0M+21.1%
Total debt$9.6M+41.0%
Total equity$638.0M-6.6%
Total assets$814.9M-3.7%

Cash flow

See full
Operating cash flow-$16.8M-452%
CapEx$201.0K+93.3%
Free cash flow-$17.0M-464%

Valuation

See full
Market cap$8.58B-64.4%
Enterprise value$8.48B-65.0%
P/E181.2×+1.3×
P/S11.2×-24.0×

Profitability

See full
Gross margin98.3%-0.2pp
Operating margin-1.1%-17.2pp
Net margin6.2%-13.4pp
FCF margin15.6%-10.2pp

Returns & leverage

See full
Return on equity7.2%-14.6pp
Debt / equity0.0×
Current ratio2.9×-0.2×

Where this comes from

Reported directly by Corcept Therapeutics in its filing.

Tagged under the XBRL concept cort:LongTermAccruedGovernmentRebates.

The official record: Corcept Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Corcept Therapeutics's long-term accrued government rebates.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Corcept Therapeutics's long-term accrued government rebates?
Corcept Therapeutics (CORT) reported long-term accrued government rebates of $4.37M in Q1 2026.
What does long-term accrued government rebates mean?
Long-term financial obligations for government-mandated drug rebates.
How do you interpret long-term accrued government rebates?
An increase may reflect higher sales volume in government-reimbursed channels or changes in regulatory rebate requirements.
How does long-term accrued government rebates compare across companies?
Specific to the pharmaceutical industry; peers with similar product portfolios will have comparable rebate structures.